BRIEF-Oncolytics reports additional data from phase II study of Reolysin

Wed Aug 10, 2016 6:48am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Aug 10 (Reuters) - Oncolytics Biotech Inc

* Oncolytics Biotech Inc. reports additional data from randomized phase II study of Reolysin in non-small cell lung cancer

* Study demonstrates statistically significant improvement in progression free survival in female patients with Adenocarcinoma

* Based on findings from IND 211, intends to include preselection of patients using genetic screening in future study protocols Source text for Eikon: Further company coverage: